Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 12226077 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Shin EY, et al. (2002) Phosphorylation of p85 beta PIX, a Rac/Cdc42-specific guanine nucleotide exchange factor, via the Ras/ERK/PAK2 pathway is required for basic fibroblast growth factor-induced neurite outgrowth. J Biol Chem 277, 44417-30 12226077
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

S682-p - ARHGEF7 (mouse) ▲
Orthologous residues
ARHGEF7 (human): S703‑p, ARHGEF7 iso1 (human): S525‑p, ARHGEF7 iso7 (human): ‑, ARHGEF7 (mouse): S682‑p, ARHGEF7 iso2 (mouse): S682‑p, ARHGEF7 iso3 (mouse): S607‑p, ARHGEF7 (rat): S525‑p
Characterization
 Methods used to characterize site in vivo:  [32P] bio-synthetic labeling, mutation of modification site
 Disease tissue studied:  adrenal cancer, pheochromocytoma
 Relevant cell lines - cell types - tissues:  PC-12 (chromaffin)
 Cellular systems studied:  cell lines
 Species studied:  rat
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
bFGF increase
PD98059 bFGF inhibit treatment-induced increase
Downstream Regulation
 Effect of modification (function):  intracellular localization

T683-p - ARHGEF7 (mouse) ▲
Orthologous residues
ARHGEF7 (human): T704‑p, ARHGEF7 iso1 (human): T526‑p, ARHGEF7 iso7 (human): ‑, ARHGEF7 (mouse): T683‑p, ARHGEF7 iso2 (mouse): T683‑p, ARHGEF7 iso3 (mouse): T608‑p, ARHGEF7 (rat): T526‑p
Characterization
 Methods used to characterize site in vivo:  [32P] bio-synthetic labeling, mutation of modification site
 Disease tissue studied:  adrenal cancer, pheochromocytoma
 Relevant cell lines - cell types - tissues:  PC-12 (chromaffin)
 Cellular systems studied:  cell lines
 Species studied:  rat
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
bFGF increase
PD98059 bFGF inhibit treatment-induced increase
Downstream Regulation
 Effect of modification (function):  intracellular localization

T203-p - ERK1 (mouse) ▲
Orthologous residues
ERK1 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Disease tissue studied:  adrenal cancer, pheochromocytoma
 Relevant cell lines - cell types - tissues:  PC-12 (chromaffin)
 Cellular systems studied:  cell lines
 Species studied:  rat
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
bFGF increase
PD98059 bFGF inhibit treatment-induced increase

Y205-p - ERK1 (mouse) ▲
Orthologous residues
ERK1 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Disease tissue studied:  adrenal cancer, pheochromocytoma
 Relevant cell lines - cell types - tissues:  PC-12 (chromaffin)
 Cellular systems studied:  cell lines
 Species studied:  rat
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
bFGF increase
PD98059 bFGF inhibit treatment-induced increase

T183-p - ERK2 (mouse) ▲
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Disease tissue studied:  adrenal cancer, pheochromocytoma
 Relevant cell lines - cell types - tissues:  PC-12 (chromaffin)
 Cellular systems studied:  cell lines
 Species studied:  rat
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
bFGF increase
PD98059 bFGF inhibit treatment-induced increase

Y185-p - ERK2 (mouse) ▲
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Disease tissue studied:  adrenal cancer, pheochromocytoma
 Relevant cell lines - cell types - tissues:  PC-12 (chromaffin)
 Cellular systems studied:  cell lines
 Species studied:  rat
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
bFGF increase
PD98059 bFGF inhibit treatment-induced increase


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.